Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Jan;23(1):45-52.
doi: 10.1111/ene.12664. Epub 2015 Feb 9.

Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis

A E Elia  1 , S Lalli  1 , M R Monsurrò  2 , A Sagnelli  2 , A C Taiello  3 , B Reggiori  1 , V La Bella  3 , G Tedeschi  2 , A Albanese  1   4
Affiliations
Randomized Controlled Trial

Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis

A E Elia et al. Eur J Neurol. 2016 Jan.

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] Eur J Neurol. 2017 Apr;24(4):659. doi: 10.1111/ene.13282. Eur J Neurol. 2017. PMID: 28322002 Free PMC article. No abstract available.

Abstract

Background and purpose: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produced in the liver and used for treatment of chronic cholestatic liver diseases. Experimental studies suggest that TUDCA may have cytoprotective and anti-apoptotic action, with potential neuroprotective activity. A proof of principle approach was adopted to provide preliminary data regarding the efficacy and tolerability of TUDCA in a series of patients with amyotrophic lateral sclerosis (ALS).

Methods: As a proof of principle, using a double-blind placebo controlled design, 34 ALS patients under treatment with riluzole who were randomized to placebo or TUDCA (1 g twice daily for 54 weeks) were evaluated after a lead-in period of 3 months. The patients were examined every 6 weeks. The primary outcome was the proportion of responders [those subjects with improvement of at least 15% in the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) slope during the treatment period compared to the lead-in phase]. Secondary outcomes included between-treatment comparison of ALSFRS-R at study end, comparison of the linear regression slopes for ALSFFRS-R mean scores and the occurrence of adverse events.

Results: Tauroursodeoxycholic acid was well tolerated; there were no between-group differences for adverse events. The proportion of responders was higher under TUDCA (87%) than under placebo (P = 0.021; 43%). At study end baseline-adjusted ALSFRS-R was significantly higher (P = 0.007) in TUDCA than in placebo groups. Comparison of the slopes of regression analysis showed slower progression in the TUDCA than in the placebo group (P < 0.01).

Conclusions: This pilot study provides preliminary clinical data indicating that TUDCA is safe and may be effective in ALS.

Trial registration: ClinicalTrials.gov NCT00877604.

Keywords: amyotrophic lateral sclerosis; cholic acids; tauroursodeoxycholic acid.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Random assignments to treatment, withdrawals during the lead‐in phase, completion of the trial, and requests for open‐label treatment. The number of patients who died during the treatment phase is also reported.
Figure 2
Figure 2
Linear regression analysis of ALSFFRS‐R mean scores over time for the TUDCA (circles, slope −0.388) and placebo groups (triangles, slope −0.262).
Figure 3
Figure 3
Kaplan–Meier estimates of the probability of survival in the placebo and TUDCA groups (P = 0.092; log‐rank test).
See this image and copyright information in PMC

Comment in

References

    1. Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. Neuropathol Appl Neurobiol 1998; 24: 104–117. - PubMed
    1. Turner MR, Bowser R, Bruijn L, et al Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2013; 14(Suppl. 1): 19–32. - PMC - PubMed
    1. Cozzolino M, Ferri A, Valle C, Carri MT. Mitochondria and ALS: implications from novel genes and pathways. Mol Cell Neurosci 2013; 55: 44–49. - PubMed
    1. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose‐ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347: 1425–1431. - PubMed
    1. Sreedharan J, Brown RH Jr. Amyotrophic lateral sclerosis: problems and prospects. Ann Neurol 2013; 74: 309–316. - PubMed

Publication types

Associated data